238 related articles for article (PubMed ID: 7568051)
1. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.
Wang Y; Rollins SA; Madri JA; Matis LA
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8955-9. PubMed ID: 7568051
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
Wang Y; Hu Q; Madri JA; Rollins SA; Chodera A; Matis LA
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8563-8. PubMed ID: 8710910
[TBL] [Abstract][Full Text] [Related]
3. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
4. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine.
Wang H; Jiang J; Liu W; Kubelik D; Chen G; Gies D; Garcia B; Zhong R; Rother RP
Transplantation; 2005 May; 79(9):1121-7. PubMed ID: 15880054
[TBL] [Abstract][Full Text] [Related]
5. A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.
Mehta G; Scheinman RI; Holers VM; Banda NK
J Immunol; 2015 Jun; 194(11):5446-54. PubMed ID: 25917104
[TBL] [Abstract][Full Text] [Related]
6. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
Kroshus TJ; Rollins SA; Dalmasso AP; Elliott EA; Matis LA; Squinto SP; Bolman RM
Transplantation; 1995 Dec; 60(11):1194-202. PubMed ID: 8525509
[TBL] [Abstract][Full Text] [Related]
7. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.
Fung M; Lu M; Fure H; Sun W; Sun C; Shi NY; Dou Y; Su J; Swanson X; Mollnes TE
Clin Exp Immunol; 2003 Aug; 133(2):160-9. PubMed ID: 12869020
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis.
Banda NK; Kraus D; Vondracek A; Huynh LH; Bendele A; Holers VM; Arend WP
Arthritis Rheum; 2002 Nov; 46(11):3065-75. PubMed ID: 12428251
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs.
Rollins SA; Matis LA; Springhorn JP; Setter E; Wolff DW
Transplantation; 1995 Dec; 60(11):1284-92. PubMed ID: 8525523
[TBL] [Abstract][Full Text] [Related]
10. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.
Williams RO; Mason LJ; Feldmann M; Maini RN
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2762-6. PubMed ID: 7908442
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species.
Zelek WM; Morgan BP
Front Immunol; 2020; 11():612402. PubMed ID: 33424866
[TBL] [Abstract][Full Text] [Related]
12. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.
Copland DA; Hussain K; Baalasubramanian S; Hughes TR; Morgan BP; Xu H; Dick AD; Nicholson LB
Clin Exp Immunol; 2010 Mar; 159(3):303-14. PubMed ID: 20002447
[TBL] [Abstract][Full Text] [Related]
13. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation.
Nandakumar KS; Bajtner E; Hill L; Böhm B; Rowley MJ; Burkhardt H; Holmdahl R
Arthritis Rheum; 2008 Jan; 58(1):184-96. PubMed ID: 18163493
[TBL] [Abstract][Full Text] [Related]
14. SND-117, a sinomenine bivalent alleviates type II collagen-induced arthritis in mice.
Zhou YR; Zhao Y; Bao BH; Li JX
Int Immunopharmacol; 2015 Jun; 26(2):423-31. PubMed ID: 25887268
[TBL] [Abstract][Full Text] [Related]
15. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells.
Fan K; Dai J; Wang H; Wei H; Cao Z; Hou S; Qian W; Wang H; Li B; Zhao J; Xu H; Yang C; Guo Y
Arthritis Rheum; 2008 Jul; 58(7):2041-52. PubMed ID: 18576331
[TBL] [Abstract][Full Text] [Related]
16. Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats.
Fischetti F; Durigutto P; Macor P; Marzari R; Carretta R; Tedesco F
Arthritis Rheum; 2007 Apr; 56(4):1187-97. PubMed ID: 17393439
[TBL] [Abstract][Full Text] [Related]
17. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.
Yoshioka T; Nakajima A; Akiba H; Ishiwata T; Asano G; Yoshino S; Yagita H; Okumura K
Eur J Immunol; 2000 Oct; 30(10):2815-23. PubMed ID: 11069062
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5.
Evans MJ; Rollins SA; Wolff DW; Rother RP; Norin AJ; Therrien DM; Grijalva GA; Mueller JP; Nye SH; Squinto SP
Mol Immunol; 1995 Nov; 32(16):1183-95. PubMed ID: 8559143
[TBL] [Abstract][Full Text] [Related]
19. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
Ohtsuji M; Lin Q; Nishikawa K; Ohtsuji N; Okazaki H; Tsurui H; Amano H; Shirai T; Nishimoto N; Nishimura H; Hirose S
Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
[TBL] [Abstract][Full Text] [Related]
20. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies.
Malfait AM; Williams RO; Malik AS; Maini RN; Feldmann M
Arthritis Rheum; 2001 May; 44(5):1215-24. PubMed ID: 11352257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
